GREAT SCIENCE. GREAT MEDICINE.
CREATING BREAKTHROUGH TREATMENTS.
HGS is working to create and develop novel therapies that can extend and improve the quality of life. That is our passion.
Three Products in Late-Stage Development
We have three promising products in late-stage development – one already commercialized and two moving toward commercialization. BENLYSTA™ (belimumab) has successfully completed Phase 3 development in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010.
ZALBIN™ (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C. We have submitted a Biologics License Application to the FDA for ZALBIN in the United States, and Novartis has submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) under the brand name JOULFERON® in Europe. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry.
In April 2009, we completed the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalational anthrax. In July 2009, we secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the Stockpile over a three-year period beginning near the end of 2009.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by mapatumumab, our TRAIL receptor antibody for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
We are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.